INS and type 2 diabetes mellitus: In the present study, we describe the results of an 18 weeks double‐blind (DB) clinical trial, assessing the effects of a 1500 mg bid of imeglimin on fasting and postprandial glucose control, investigating insulin secretion and sensitivity using an OGTT in Caucasian T2D patients that were on metformin monotherapy and washed out for 4 weeks before the start of imeglimin treatment.